Dialyze Direct Fl is a medicare approved dialysis facility center in Boca Raton, Florida and it has 1 dialysis stations. It is located in Palm Beach county at 1601 Clint Moore Ave #160, Boca Raton, FL, 33487. You can reach out to the office of Dialyze Direct Fl at (561) 609-3100. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Dialyze Direct Fl has the following ownership type - Profit. It was first certified by medicare in September, 2015. The medicare id for this facility is 682588 and it accepts patients under medicare ESRD program.
| Name | Dialyze Direct Fl |
|---|---|
| Location | 1601 Clint Moore Ave #160, Boca Raton, Florida |
| No. of Dialysis Stations | 1 |
| Medicare ID | 682588 |
| Managed By | Independent |
| Ownership Type | Profit |
| Late Shifts | No |
| 1601 Clint Moore Ave #160, Boca Raton, Florida, 33487 | |
| (561) 609-3100 | |
News Archive
Psychologists are to improve online health information on lung cancer after research showed that family members are more likely to search online to encourage loved ones to seek help.
NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.
Traditionally, we use biopsies to try to predict how cancer spreads. There are a number of molecular markers that are used, but biopsy is a limited approach. Now, the current trend is to use liquid biopsy, which is basically a blood sample.
The University of Pittsburgh, Carnegie Mellon University, and the University of Pittsburgh Medical Center will be hosting 12 science and technology tours Sept. 21 in conjunction with the G20 Pittsburgh Summit Sept. 24-25. These tours of cutting-edge research and development will help explain how and why the "eds and meds" sector of Pittsburgh's economy has become a powerful driver of the region's success.
AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.
› Verified 2 days ago
| NPI Number | 1588065510 |
| Doing Business As | Dialyze Direct Fl Llc |
| Address | 1601 Clint Moore Rd Boca Raton, Florida, 33487 |
| Phone Number | (561) 609-3100 |
News Archive
Psychologists are to improve online health information on lung cancer after research showed that family members are more likely to search online to encourage loved ones to seek help.
NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.
Traditionally, we use biopsies to try to predict how cancer spreads. There are a number of molecular markers that are used, but biopsy is a limited approach. Now, the current trend is to use liquid biopsy, which is basically a blood sample.
The University of Pittsburgh, Carnegie Mellon University, and the University of Pittsburgh Medical Center will be hosting 12 science and technology tours Sept. 21 in conjunction with the G20 Pittsburgh Summit Sept. 24-25. These tours of cutting-edge research and development will help explain how and why the "eds and meds" sector of Pittsburgh's economy has become a powerful driver of the region's success.
AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 9 |
News Archive
Psychologists are to improve online health information on lung cancer after research showed that family members are more likely to search online to encourage loved ones to seek help.
NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.
Traditionally, we use biopsies to try to predict how cancer spreads. There are a number of molecular markers that are used, but biopsy is a limited approach. Now, the current trend is to use liquid biopsy, which is basically a blood sample.
The University of Pittsburgh, Carnegie Mellon University, and the University of Pittsburgh Medical Center will be hosting 12 science and technology tours Sept. 21 in conjunction with the G20 Pittsburgh Summit Sept. 24-25. These tours of cutting-edge research and development will help explain how and why the "eds and meds" sector of Pittsburgh's economy has become a powerful driver of the region's success.
AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 1 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 5 |
| Percentage of adult patients getting regular hemodialysis at the center | |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Psychologists are to improve online health information on lung cancer after research showed that family members are more likely to search online to encourage loved ones to seek help.
NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.
Traditionally, we use biopsies to try to predict how cancer spreads. There are a number of molecular markers that are used, but biopsy is a limited approach. Now, the current trend is to use liquid biopsy, which is basically a blood sample.
The University of Pittsburgh, Carnegie Mellon University, and the University of Pittsburgh Medical Center will be hosting 12 science and technology tours Sept. 21 in conjunction with the G20 Pittsburgh Summit Sept. 24-25. These tours of cutting-edge research and development will help explain how and why the "eds and meds" sector of Pittsburgh's economy has become a powerful driver of the region's success.
AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Dialyze Direct Fl with elevated calcium levels.
| Patients with hypercalcemia | 23 |
| Hypercalcemia patient months | 160 |
| Patients with Serumphosphor | 33 |
| Patients with Serumphosphor less than 3.5 mg/dL | 24 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 50 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 17 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 6 |
| Patients with Serumphosphor greater than 7 mg/dL | 2 |
News Archive
Psychologists are to improve online health information on lung cancer after research showed that family members are more likely to search online to encourage loved ones to seek help.
NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.
Traditionally, we use biopsies to try to predict how cancer spreads. There are a number of molecular markers that are used, but biopsy is a limited approach. Now, the current trend is to use liquid biopsy, which is basically a blood sample.
The University of Pittsburgh, Carnegie Mellon University, and the University of Pittsburgh Medical Center will be hosting 12 science and technology tours Sept. 21 in conjunction with the G20 Pittsburgh Summit Sept. 24-25. These tours of cutting-edge research and development will help explain how and why the "eds and meds" sector of Pittsburgh's economy has become a powerful driver of the region's success.
AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 35 |
| Patient months included in arterial venous fistula and catheter summaries | 128 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 49 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 46 |
News Archive
Psychologists are to improve online health information on lung cancer after research showed that family members are more likely to search online to encourage loved ones to seek help.
NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.
Traditionally, we use biopsies to try to predict how cancer spreads. There are a number of molecular markers that are used, but biopsy is a limited approach. Now, the current trend is to use liquid biopsy, which is basically a blood sample.
The University of Pittsburgh, Carnegie Mellon University, and the University of Pittsburgh Medical Center will be hosting 12 science and technology tours Sept. 21 in conjunction with the G20 Pittsburgh Summit Sept. 24-25. These tours of cutting-edge research and development will help explain how and why the "eds and meds" sector of Pittsburgh's economy has become a powerful driver of the region's success.
AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 37 |
| Hospitalization Rate in facility | 282.8 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 474.2 |
| Hospitalization Rate: Lower Confidence Limit | 175.7 |
News Archive
Psychologists are to improve online health information on lung cancer after research showed that family members are more likely to search online to encourage loved ones to seek help.
NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.
Traditionally, we use biopsies to try to predict how cancer spreads. There are a number of molecular markers that are used, but biopsy is a limited approach. Now, the current trend is to use liquid biopsy, which is basically a blood sample.
The University of Pittsburgh, Carnegie Mellon University, and the University of Pittsburgh Medical Center will be hosting 12 science and technology tours Sept. 21 in conjunction with the G20 Pittsburgh Summit Sept. 24-25. These tours of cutting-edge research and development will help explain how and why the "eds and meds" sector of Pittsburgh's economy has become a powerful driver of the region's success.
AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at Dialyze Direct Fl were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 42.6 (Worse than Expected) |
| Readmission Rate: Upper Confidence Limit | 53.7 |
| Readmission Rate: Lower Confidence Limit | 31.7 |
News Archive
Psychologists are to improve online health information on lung cancer after research showed that family members are more likely to search online to encourage loved ones to seek help.
NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.
Traditionally, we use biopsies to try to predict how cancer spreads. There are a number of molecular markers that are used, but biopsy is a limited approach. Now, the current trend is to use liquid biopsy, which is basically a blood sample.
The University of Pittsburgh, Carnegie Mellon University, and the University of Pittsburgh Medical Center will be hosting 12 science and technology tours Sept. 21 in conjunction with the G20 Pittsburgh Summit Sept. 24-25. These tours of cutting-edge research and development will help explain how and why the "eds and meds" sector of Pittsburgh's economy has become a powerful driver of the region's success.
AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.
› Verified 2 days ago